Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec;298(Pt B):137-147.
doi: 10.1016/j.expneurol.2017.10.001. Epub 2017 Oct 5.

Neuroprotection and Neurorestoration as Experimental Therapeutics for Parkinson's Disease


Neuroprotection and Neurorestoration as Experimental Therapeutics for Parkinson's Disease

Veronica Francardo et al. Exp Neurol. .


Disease-modifying treatments remain an unmet medical need in Parkinson's disease (PD). Such treatments can be operationally defined as interventions that slow down the clinical evolution to advanced disease milestones. A treatment may achieve this outcome by either inhibiting primary neurodegenerative events ("neuroprotection") or boosting compensatory and regenerative mechanisms in the brain ("neurorestoration"). Here we review experimental paradigms that are currently used to assess the neuroprotective and neurorestorative potential of candidate treatments in animal models of PD. We review some key molecular mediators of neuroprotection and neurorestoration in the nigrostriatal dopamine pathway that are likely to exert beneficial effects on multiple neural systems affected in PD. We further review past and current strategies to therapeutically stimulate these mediators, and discuss the preclinical evidence that exercise training can have neuroprotective and neurorestorative effects. A future translational task will be to combine behavioral and pharmacological interventions to exploit endogenous mechanisms of neuroprotection and neurorestoration for therapeutic purposes. This type of approach is likely to provide benefit to many PD patients, despite the clinical, etiological, and genetic heterogeneity of the disease.

Keywords: 6-Hydroxydopamine; Axon sprouting; Growth factor; MPTP; Neurotrophin; Sigma-1 receptor; Synaptic plasticity; Synuclein.

Similar articles

See all similar articles

Cited by 14 articles

See all "Cited by" articles

Publication types